Effect Of Piperine In Patients With Oropharyngeal Dysphagia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Piperine acts on the oropharyngeal TRPV1, increasing sensory input and the release of substance P. These actions may accelerate the oropharyngeal swallow response, improving the swallowing of dysphagic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Buspirone for Functional Dysphagia

NCT02674412

Functional Dysphagia Ineffective Esophageal Motility

COMPLETED NA

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

NCT02447315

Healthy Subjects

COMPLETED PHASE1

Nicergoline Use in Dysphagia Patients

NCT05551182

Dysphagia

UNKNOWN PHASE3

Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD

NCT04301726

Huntington Disease

TERMINATED PHASE1

Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics

NCT03790345

Schizophrenia Drug Induced Movement Disorder, Unspecified Oxidative Stress

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deglutition Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Piperine Dose 1

Piperine 1 mM

Group Type EXPERIMENTAL

Piperine

Intervention Type DRUG

Piperine Dose 2

Piperine 150 microM

Group Type EXPERIMENTAL

Piperine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Piperine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\>18
* History of swallowing difficulties associated with aging and/or neurological diseases (neurodegenerative or non-progressive neurological diseases)
* Study explained and written subject information given
* Informed consent signed

Exclusion Criteria

* Patients suffering idiosyncratic phenomena or who are allergic to any medication, especially iodinated contrast media
* Patients suffering major respiratory disease or undergoing any type of surgery in the three months prior to the study
* Patients with a background of alcohol dependence or other drug dependence
* Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No